Sunday, June 4, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Blood Sterilization Takes Out Helpful RNA

by Global Biodefense Staff
June 13, 2014
Platelets and Viruses

Platelets and VirusesCertain processes used to sterilize blood products could potentially cause serious health issues in transfusion recipients, according to an international study published in the journal Platelets and led by Dr. Patrick Provost of Université Laval’s Faculty of Medicine and the CHU de Québec Research Center.

These processes purportedly alter the blood platelets to the extent of preventing them from carrying out their functions correctly and may be the cause of hemorrhages observed in patients having received treated blood.

The function of platelets goes far beyond their role in blood coagulation and wound healing. They contain up to a third of the human genome in the form of ribonucleic acid (RNA), allowing them to synthesize over 1,000 proteins essential to the normal functioning of the human body.

The presence of this genetic material explains why platelets are affected by pathogen reduction treatments. “The processes that are used target the genetic material of pathogenic organisms,” explains Patrick Provost. “They were developed more than 20 years ago, before we understood the importance of the genetic material contained in platelets.”

Dr. Provost and his colleagues discovered that these treatments activate blood platelets, triggering the release of RNA. “The platelets end up depleted of RNA so, once transfused, they’re unable to do what they normally would,” says the researcher.

The treatments are already on the market in some European countries, notably Switzerland, France, and Germany. Manufacturers are trying to get approval in other countries, including Canada and the United States. Professor Provost regrets the dearth of independent studies that have focused on the safety of the processes and hopes regulatory authorities such as Health Canada and the U.S. Food and Drug Administration will take these results into consideration. “In light of what we have demonstrated, the potentially harmful effects of these treatments should be carefully evaluated in the countries where they are not yet approved. It should also be re-evaluated in those countries where they are,” concludes Provost.

Article courtesy of Université Laval.

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC